Navigation Links
Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
Date:11/1/2011

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale.  

Back-up Compounds --

A total of ~640 analogs were synthesized by Epix and/or Amgen chemists to explore the SAR of several chemical series including the two lead series:  benzofurans (AMG 277) and benzothiazoles (AMG 369).  Six of these compounds were profiled in a preliminary 4d non-GLP rat toxicology study based on their attractive potency, selectivity, ADME, and efficacy profiles.  Based on these results, four compounds were profiled further in a 14d non-GLP rat toxicology study and two of these compounds were profiled in a monkey 14d non-GLP toxicology study.  

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office -- jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Credito
'/>"/>

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
2. Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale
3. S1P1 Lead Compounds, AMG 369 and AMG 277, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
6. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
7. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
11. Caliper Continues Participation in EPAs Expanded ToxCast Program; Receives Remaining Phase II Compounds for Screening in Fourth Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
(Date:8/29/2014)... 29, 2014 Does your doctor know what you,re ... have recommended marijuana to the over 112,000 currently registered patients ... majority of the other roughly 20,300+ active physicians listed with ... about it – even though a poll in February 2014 ... they have tried it. "With marijuana legalization ...
(Date:8/29/2014)... , August 29, 2014 ... by Product & Services (Equipment, Reagent, Primer, Probe, ... (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) ... the global Oligonucleotide Synthesis Market is expected to ... in 2014, growing at a CAGR of 9.8% ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Dec. 22, 2011 Over 130 organizations, community leaders, ... neighborhoods and inner-cities across the country today urged Express ... Walgreens. This agreement is necessary to protect access to pharmacy ... "We strongly urge Express Scripts to put the people ...
... Biopharmaceuticals Corp. ("Provenance") announced today the closing of ... LLC for the continued development of anti-cancer therapeutic, ... of molecules called immunocytokines that are being developed ... Immunocytokines, combine the immune stimulating features of cytokines ...
Cached Medicine Technology:Over 130 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 Cosmetic Town ... knowledge and authenticity of its doctors. Cosmetic Town ... the most renowned doctors in their field are chosen ... assure patients have a direct link to potentially hundreds ... doctors will be able to communicate through the site’s ...
(Date:8/29/2014)... CO (PRWEB) August 29, 2014 Panic ... attack is the feeling of intense stress and fear, ... life of the sufferer, causing insecurity and affecting relationships. ... factors and there are many symptoms that patients can ... are among these symptoms. Overcoming panic attacks is extremely ...
(Date:8/29/2014)... Daily Gossip indicates in its recently published review that ... what patients have to go through at the development of ... this new method. Bakker is a naturopathic doctor who has ... Bakker claims that during all this time he had heard ... the yeast infection can be. , Read more about ...
(Date:8/29/2014)... Developed as a nod to post-war ... Canada Goose products offer the mobility, durability and ... runways. The company’s Canada Goose Chilliwack bombers ... market. Additionally, the firm has unveiled its new bomber ... At present, all high quality Chilliwack bombers are provided ...
(Date:8/29/2014)... August 29, 2014 As reported by CNN.com ... (8/15), the process of admitting that you need help ... The article acknowledges and highlights the fact that if you ... may be very overwhelmed by all of the information that ... impossible to sift through, it is still possible to get ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:Candida Crusher Review Reveals a Unique Way to Eliminate Yeast Infection Permanently 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3
... OXFORD, England, July 13 International medical,communications ... the Year at the Communique Awards in London ... by an independent panel of,communications experts, who assess ... for healthcare clients, along with business strategy,client retention, ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), a ... scheduled a conference call and web cast on Thursday, July 30, 2009, ... ended June 28, 2009. Gentiva plans to issue its financial news release ... , The conference call is open to investment analysts ...
... July 13 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for the treatment ... has received a $1.5 million milestone payment from Biogen ... of a Raf kinase inhibitor development candidate for the ...
... New data pooled from four large, "real world" ... VIII (rFVIII-FS) reduced bleeding and provided data regarding ... mild-to-severe hemophilia A. Additionally, rates of inhibitor formation ... untreated patients. The data were presented at the ...
... , SUNNYVALE, Calif., July 13 Cepheid (Nasdaq: CPHD ... & Drug Administration (FDA) to market its Xpert(R) C. difficile ... of the bacterium that causes Clostridium difficile infection (CDI). ... for CDI to deliver both rapid turnaround and a high degree ...
... , PORT WASHINGTON, N.Y., July 13 ... of the American Medical Association has granted a CPT Category ... (TM) (MCG) system. MCG is the World,s first Internet based, ... for interactive online diagnosis. The MCG is intended as ...
Cached Medicine News:Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 2Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 3Health News:Gentiva(R) Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday, July 30, 2009 4Health News:Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 2Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 3Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 4Health News:Analysis of Four Large Post-Marketing Surveillance Studies Describe Clinical Effects of Sucrose-Formulated Recombinant Factor VIII 5Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 2Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 3Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 4Health News:Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection 5Health News:AMA Grants New Category III CPT Code to Premier Heart's Multifunction CardioGram(TM) (MCG) 2
... (OSS) from Biomet Inc. offers the ... specifically for orthopaedic surgeons and oncologists ... their patients: significant bone loss, ligamentous ... arthroplasties, and multiple hip revision arthroplasties. ...
DePuy's Shoe Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate matter and body fluids....
... The Nidek NM-200D's compact, lightweight body ... more options to treat more patients, more ... ease of operation and functionality for image ... image data to the compact flash card. ...
... Laboratory is a comprehensive, ... manages specimen data from ... tracking to final cumulative ... is a multi-module system ...
Medicine Products: